BACKGROUND Few cases of falsely undetectable PSA due to the presence of an inhibitory serum factor have been reported in the world literature. We present a case of falsely low-to-undetectable PSA with data from a serum dilution series, the current literature on biochemical assay interference, and the implications for prostate cancer salvage treatment. CASE REPORT A 63-year-old man was treated with prostatectomy for high-risk prostate cancer and was found to have a rising PSA after approximately 3 years following surgery. He subsequently transferred his care to a different health system and was found to have an undetectable PSA. He was eventually found to have an elevated PSA once again after the particular assay at this institution was changed. He thus received salvage prostate radiotherapy and androgen deprivation therapy. CONCLUSIONS While falsely low PSA results cannot be explained by the presence of serum heterophile antibodies, competitive antibody interference against the immunoassay reagents or anti-PSA antibodies are possible explanations for the results of the dilution experiments performed in this case study. We suggest that unexpected PSA testing results should raise concern for assay interference and warrant further clinical workup.
|Original language||English (US)|
|Number of pages||5|
|Journal||American Journal of Case Reports|
|State||Published - 2019|
Bibliographical noteFunding Information:
The authors of this paper would like to acknowledge the University of Minnesota Department of Radiation Oncology for providing financial and general support in the preparation of this manuscript.
© Am J Case Rep, 2019.
- Immunoenzyme Techniques
- Prostate-Specific Antigen
- Prostatic Neoplasms
PubMed: MeSH publication types
- Journal Article